朱 冰, 杨建茹①, 江跃全, 陈诗奉, 付新平. 嗜肿瘤I 型单纯疱疹病毒介导GALVfus 基因治疗肺腺癌的体外试验研究*[J]. 中国肿瘤临床, 2010, 37(22): 1261-1264. DOI: 10.3969/j.issn.1000-8179.2010.22.001
引用本文: 朱 冰, 杨建茹①, 江跃全, 陈诗奉, 付新平. 嗜肿瘤I 型单纯疱疹病毒介导GALVfus 基因治疗肺腺癌的体外试验研究*[J]. 中国肿瘤临床, 2010, 37(22): 1261-1264. DOI: 10.3969/j.issn.1000-8179.2010.22.001
ZHU Bing1, YANG Jianru2, JIANG Yuequan1, CHEN Shifeng1, FU Xinping1. Antitumor Therapy with GALV Membrane Fusion Glycoprotein Mediated by Type I Herpes Simplex Virus for Lung Adenocarcinoma in vitro[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(22): 1261-1264. DOI: 10.3969/j.issn.1000-8179.2010.22.001
Citation: ZHU Bing1, YANG Jianru2, JIANG Yuequan1, CHEN Shifeng1, FU Xinping1. Antitumor Therapy with GALV Membrane Fusion Glycoprotein Mediated by Type I Herpes Simplex Virus for Lung Adenocarcinoma in vitro[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(22): 1261-1264. DOI: 10.3969/j.issn.1000-8179.2010.22.001

嗜肿瘤I 型单纯疱疹病毒介导GALVfus 基因治疗肺腺癌的体外试验研究*

Antitumor Therapy with GALV Membrane Fusion Glycoprotein Mediated by Type I Herpes Simplex Virus for Lung Adenocarcinoma in vitro

  • 摘要: 目的:探讨特异性启动子UL38及无肿瘤特异性巨细胞病毒启动子(CMVP)调控的嗜肿瘤I 型单纯疱疹病毒(HSV-I)介导的长臂猿白血病病毒致融性外膜糖蛋白(GALV.fus )基因系统体外对人肺腺癌的选择性杀伤效应。方法:选择非洲绿猴肾细胞(Vero ),肺腺癌细胞(A549)和正常人胚胎成纤维细胞(HFL-I GNHu 5),将构建成功的重组HSV-I 载体通过脂质体转染、导入包装细胞Vero 中制备重组HSV-I 病毒,用来转染A549 和HFL-I GNHu 5,观察其转染、表达状况及体外抗肿瘤作用,增强型绿色荧光蛋白(EGFP)基因片段取代GALV.fus 作对照质粒。提取受染A549 和HFL-I GNHu 5 细胞的总蛋白,以Western Blot法鉴定GALV.fus 基因的表达。结果:成功包装重组HSV-I 载体,致融性病毒感染A549 后引起强烈的细胞膜融合,且杀伤作用随着感染剂量的增加而增强。而非致融病毒仅引起病毒细胞毒性效应,细胞呈圆形,镜下未见细胞融合斑。CMVP 调控的重组HSV-I 在HFL-I GNHu 5 生长静止抑制状态均引起细胞膜融合,UL38P 调控的重组HSV-I 仅在生长状态导致细胞膜融合;而细胞处于静止和抑制状态时,不引起细胞膜融合以及任何细胞病理改变。以Western Blot法检测受染A549 和HFL-I GNHu 5 细胞,均可检到GALV.fus 基因蛋白表达。结论:UL38p 调控的GALV.fus 基因在有效的载体内对体外肺癌细胞有强效的选择性杀伤效果和应用安全性,为临床肺癌治疗探索出一种新型基因治疗方法。

     

    Abstract: Objective:To observe the selective killing effect of a recombinant TypeI Herpes simplex virus (HSV-I)-me-diated Gibbon ape leukemia virus membrane fusion glycoprotein (GALV.fus) gene system controlled by UL38and cytomeg -alovirus (CMV) promoters on lung adenocarcinomain vitro . Methods:Lung adenocarcinoma cell line A 549 , human fetal fi -broblast cell line HFL- I GNHu5 and Vero green monkey kidney cells were cultured for study. Recombinant HSV-I plasmids encoding GALV.fus were introduced into Vero cells by liposome to amplify the virus, and then the virus was transfected into A549 and HFL-I GNHu 5 cells. The expression of the recombinant plasmids and antitumor effect in vitro were observed. Recombinant cytomegalovirus (CMV) containing GALV.fus or enhanced green fluorescence protein was used as the con-trol. Total protein was extracted from the transfected A 549 and HFL-I GNHu5 cells, and expression of the GALV.fus gene was detected by Western Blot.Results: Recombinant HSV-I virus was packed successfully. The GALV.fus gene system caused A549 cells to form syncytia in vitro and showed increasing cell death with increasing multiplicity of infection. On the other hand, infection with the control virus induced a typical cytopathic effect, characterized by the cells becoming rounder and swelling. HSV Synco- 2 was tested for loss of its ability to cause syncytial formation in normal non-dividing human cells by infecting primary human fibroblasts in either a quiescent or a cycling state. Infection with recombinant HSV- I mediated GALV.fus gene system caused syncytial formation in these normal human cells when they were cycling. CMV promoter-me-diated cell fusion was only marginally affected in cells whose cycling was either slowed by serum starvation or completely arrested with lovastatin. UL38promoter-mediated cell fusion, on the other hand, was absent in cells whose cycling was decreased or arrested. By Western Blot, the expression of GALV.fus gene could be detected in both A549 cells and embryonic fibroblasts transfected by recombinant HSV- I virus. Conclusion:GALV.fus gene system controlled by the UL38promoter has a powerful selective killing effect against lung adenocarcinoma cells invitro , and this system may be a promising new candidate for gene therapy for lung cancer.

     

/

返回文章
返回